Log in
Enquire now
‌

US Patent 11332535 Anti-CD123 antibodies and conjugates and derivatives thereof

Patent 11332535 was granted and assigned to ImmunoGen on May, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
ImmunoGen
ImmunoGen
Current Assignee
ImmunoGen
ImmunoGen
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11332535
Date of Patent
May 17, 2022
Patent Application Number
17077877
Date Filed
October 22, 2020
Patent Citations
‌
US Patent 10875925 Anti-CD123 antibodies and conjugates and derivatives thereof
‌
US Patent 10077313 Anti-CD123 antibodies and conjugates and derivatives thereof
‌
US Patent 10287256 Selective sulfonation of benzodiazepine derivatives
‌
US Patent 10442865 Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof
‌
US Patent 10919969 Anti-CD123 antibodies and conjugates and derivatives thereof
Patent Primary Examiner
‌
Thomas S Heard

The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the α chain of the interleukine 3 receptor, or IL-3Rα). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11332535 Anti-CD123 antibodies and conjugates and derivatives thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us